<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43472">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01817725</url>
  </required_header>
  <id_info>
    <org_study_id>ChangGungMH 101-3594A3</org_study_id>
    <nct_id>NCT01817725</nct_id>
  </id_info>
  <brief_title>Effect of Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg—a Pilot Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      The HBsAg clearance rate in interferon-treated responders is significantly higher than that
      in lamivudine-treated responders, implying immune control is the key to HBsAg clearance.
      There is a good chance to further increase the cure rate if the investigators can enhance
      the HBV-specific immune response when the HBsAg level already comes to a low level.

      Hypothesis: HBsAg-based vaccine can enhance HBsAg clearance in chronic hepatitis B patients
      whose HBsAg already &lt;=2000 IU/ml.

      Patients and methods:

      This pilot study will enroll 20 chronic hepatitis B patients with HBsAg ≦2000 IU/ml, no
      hepatic decompensation, no HIV coinfection, nor clinical immunodeficiency. Engerix-B vaccine
      (20μg for &lt;20 years old and 40 μg for ≥ 20 years old) will be given every 2 months for one
      year. HBsAg quantification, anti-HBs, and HBV DNA will be surveyed regularly before each
      dose during the treatment period and every 3 months for another year following the last
      dose. Viral and cellular factors will be studied to discover determinants affecting HBsAg
      clearance.

      Aims

        1. To elucidate whether HBsAg-based vaccine can reactivate host immunity to eliminate
           chronic HBV infection in patients with low titer HBsAg.

        2. To delineate the doses to response (HBsAg clearance or decline rate) correlation so as
           to design a feasible schedule for future clinical trials in a larger group of patients.

        3. To discover viral and host factors which can be used as biomarkers for personalized
           vaccine therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccination schedule:

      Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) will be administered intramuscularly at 0,
      2, 4, 6, 8, 10, 12 months or until HBsAg clearance. The dosage will be 20μg in those &lt;= 20
      years old and 40μg in those &gt; 20 years old.

      HBsAg and anti-HBs:

      qHBsAg will be checked by commercial kits (Elecsys, Roche Diagnostics, Indianapolis, IN) at
      baseline, right before every dose, and every 3 months following the last dose  for one year.
      ALT, AST, Alpha-fetoprotein, bilirubin and anti-HBs will be checked simultaneously.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HBsAg clearance</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs seropositivity</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Engerix-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) will be administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months or until HBsAg clearance. The dosage will be 20μg in those &lt;= 20 years old and 40μg in those &gt; 20 years old.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV vaccine (Engerix B)</intervention_name>
    <description>Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) will be administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months or until HBsAg clearance. The dosage will be 20μg in those &lt;= 20 years old and 40μg in those &gt; 20 years old.</description>
    <arm_group_label>Engerix-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Naïve or treated chronic hepatitis B patients with positive HBsAg and negative HBeAg;

          2. Quantitative serum HBsAg (qHBsAg) &lt;2000 IU/ml;

          3. No HIV co-infection;

          4. No obvious immunodeficiency (such as renal failure, chemotherapy, radiotherapy,
             immunosuppressant);

          5. Aged 3 to 80 years;

        Exclusion Criteria:

          1. Pregnancy

          2. Allergic to HBV vaccine or yeast.

          3. Hepatic decompensation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Wei Lai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chao-Wei Hsu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chau-Ting Yeh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Wei Lai, M.D., Ph.D.</last_name>
    <phone>886-3-3281200</phone>
    <phone_ext>8969</phone_ext>
    <email>a22141@adm.cgmh.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan Xian</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming-Wei Lai</last_name>
      <phone>886-3-3281200</phone>
      <phone_ext>8969</phone_ext>
    </contact>
    <investigator>
      <last_name>Ming-Wei Lai, M.D., Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chao-Wei Hsu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chau-Ting Yeh, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 22, 2013</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Ming-Wei Lai</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Therapeutic vaccine</keyword>
  <keyword>HBsAg clearance</keyword>
  <keyword>Immune clearance</keyword>
  <keyword>HBsAg clearance induced by vaccination</keyword>
  <keyword>s seroconversion in carriers after vaccination</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
